Dr. Noakes explained that conventional medicine and
Big Pharma continue to ignore two key problems, which are decreased life expectancy and financial destruction of the healthcare system.
Check out this article on BioJobBlog,
Big Pharma Continues to Shed Large Numbers of Jobs.
Big pharma continues to go through some big changes.
Not exact matches
Giddying merry - go - round of
pharma deals
continues as Israeli company creates the world's
biggest maker of generics.
While Tesaro is remaining publicly coy for now, a buyout has always been in the cards as
big pharma companies
continue to snap up biotechs that have already done drug development legwork for them.
«
Big pharma has been fairly resilient, with pharmaceutical firms
continuing to hire for drug development.
(See:
Big Pharma's
Continued Failure to Develop an Effective Alzheimer's Drug: Are Alzheimer's Vaccines Next?)
Medical trade associations, the
Big Pharma cartel, and processed food producers
continue to insist that high fat low carb diets such as the ketogenic diet will kill people, because humans must have a steady external supply of glucose to survive.
It began with the Flexner Report and
continues with
Big Pharma.
In general I'm very sympathetic to this kind of perspective, and a concerted focus on diet, lifestyle, sleep, exercise, and social support is desperately overdue in mainline psychiatry, where a psychologically blind reductionism has sold us the patently false notion that Axis I conditions can be easily reduced to a few simple molecular correlates (the «meme» of a simple «chemical imbalance»), an idea that has been exposed scientifically, but which
continues to generate staggering profits for
big Pharma.
The latter is expected to accumulate annual «
Continuing Medical Education (CME)» credits by reading journal articles, writing quizzes, and attending conferences — and most of the CME courses are funded in a roundabout way by
Big Pharma.
These
pharma - backed venture funds
continue to play a
big role in supplementing traditional VCs» coffers.
Oncology drug development
continues to see a high level of activity and funding across the US, despite an uncertain regulatory environment that has left many
Big Pharma companies carefully considering their R&D investments and strategies.
A number of
big pharma will
continue to drive M&A activity through 2015 & 2016 where larger companies such as Pfizer and Teva have both the appetite and the cashflow to look at investments that support existing divisions.